Edition:
India

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

51.03USD
24 Nov 2017
Change (% chg)

$0.88 (+1.76%)
Prev Close
$50.15
Open
$50.02
Day's High
$51.23
Day's Low
$50.02
Volume
151,408
Avg. Vol
309,547
52-wk High
$63.40
52-wk Low
$46.65

Chart for

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $7,913.33
Shares Outstanding(Mil.): 153.66
Dividend: --
Yield (%): --

Financials

BRIEF-Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA

* Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA

16 Nov 2017

BRIEF-ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA

* ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA

26 Oct 2017

BRIEF-ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24

* ‍Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION​

26 Oct 2017

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million

27 Jul 2017

BRIEF-Alkermes announces positive preliminary topline results

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

30 Jun 2017

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

12 Jun 2017

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

08 Jun 2017

Competitors

Earnings vs. Estimates